Critical Contrast: NeuroSense Therapeutics (NASDAQ:NRSN) vs. Zentalis Pharmaceuticals (NASDAQ:ZNTL)

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and NeuroSense Therapeutics (NASDAQ:NRSN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

Earnings & Valuation

This table compares Zentalis Pharmaceuticals and NeuroSense Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zentalis Pharmaceuticals	$67.43 million	4.20	-$137.06 million	($1.73)	-2.30
NeuroSense Therapeutics	N/A	N/A	-$11.12 million	($0.54)	-1.51

NeuroSense Therapeutics has lower revenue, but higher earnings than Zentalis Pharmaceuticals. Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than NeuroSense Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Zentalis Pharmaceuticals and NeuroSense Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zentalis Pharmaceuticals	N/A	-53.61%	-40.67%
NeuroSense Therapeutics	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Zentalis Pharmaceuticals and NeuroSense Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zentalis Pharmaceuticals	1	4	2	0	2.14
NeuroSense Therapeutics	1	1	2	1	2.60

Zentalis Pharmaceuticals currently has a consensus target price of $5.83, indicating a potential upside of 46.57%. NeuroSense Therapeutics has a consensus target price of $8.50, indicating a potential upside of 945.77%. Given NeuroSense Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe NeuroSense Therapeutics is more favorable than Zentalis Pharmaceuticals.

Institutional & Insider Ownership

1.0% of NeuroSense Therapeutics shares are owned by institutional investors. 1.9% of Zentalis Pharmaceuticals shares are owned by company insiders. Comparatively, 27.4% of NeuroSense Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Volatility & Risk

Zentalis Pharmaceuticals has a beta of 1.97, suggesting that its stock price is 97% more volatile than the S&P 500. Comparatively, NeuroSense Therapeutics has a beta of 1.56, suggesting that its stock price is 56% more volatile than the S&P 500.

Summary

NeuroSense Therapeutics beats Zentalis Pharmaceuticals on 10 of the 12 factors compared between the two stocks.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

About NeuroSense Therapeutics

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson’s disease; and CogniC for the treatment of Alzheimer’s disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.